Recommendations For Testing The Diabetogenic Activity Of Streptozotocin

DOI: 10.29296/2618723X-2018-03-09

M.А. Kovaleva(1), E.V. Shekunova(2), V.A. Kashkin(2), М.N. Makarova(1), V.G. Makarov(2) 1-JSC Research-and-manufacturing company «Houm оf Pharmacy», Leningradskiy region, Vsevolozhskiy district, Kuzmolovskiy, st. Zavodskaya, 3. b. 245, 188663, Russia; 2-CJSC «Institute of experimental pharmacology» Leningradskiy region, Vsevolozhskiy district, Kuzmolovskiy, st. Zavodskaya, 3. b. 245, 188663, Russia

Keywords: streptozotocin quality biological testing experimental diabetes

For citation:

Kovaleva M.А., Shekunova E.V., Kashkin V.A., Makarova М.N., Makarov V.G. Recommendations For Testing The Diabetogenic Activity Of Streptozotocin. Laboratory Animals for Science. 2018; 3.


Currently streptozotocin (STZ) is the most common diabetogenic substance used to model experimental diabetes mellitus on different types of laboratory animals during last 50 years. It should be noted that there are no organizations on the territory of the Russian Federation that manufacture the substance of STZ. The of Russian scientific centers purchase STZ in foreign organizations. Despite the introduction of production standards around the world, depending on the manufacturer, the quality of STZ, including physicochemical and biological properties is very different. Also special attention is required by the conditions of transportation of STZ, which require compliance with the temperature conditions of storage and transport of substance specified by the manufacturer. To ensure the rational conduct of preclinical research and the principles of humane treatment of laboratory animals, it is recommended to get biological testing of each new pack of STZ in small rodents: rats and mice. Biological testing of STZ should also be executed for an already opened pack that was stored for more than 5 months after the first opening.


  1. Rakieten N., Rakieten M.L., Nadkarni M.V. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep. 1963. 29: 91–8.
  2. Kishore L., Kajal A., Kaur N. Role of Nicotinamide in Streptozotocin Induced Diabetes in Animal Models. JETR. 2017. Vol. 2(1): 001-004. DOI: 10.19080/JETR.2017.02.555577.
  3. Ghasemi A., Khalifi S., Jedi S. Streptozotocin-nicotinamide-induced rat model of type 2 diabetes (Review). Acta Physiologica Hungarica. 2014. Vol. 101 (4): 408–20. DOI:10.1556/APhysiol.101.2014.4.2.
  4. Piepper A.A., Verma A., Zhang J., Snyder S.H. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends in Pharmacological Sciences. 1999. Vol. 20: 171–81.
  5. Okamoto H. Okamoto model for B-cell damage: Recent advances. Lessons from animal diabetes. 1996: 97–111.
  6. Etuk E.U. Animal models for studying diabetes mellitus. Agric Biol J N Am. 2010. Vol. 1 (2): 130–4.
  7. Hayashi K., Kojima R., Ito M. Strain differences in the diabetogenic activity of streptozotocin in mice. Biol Pharm Bull. 2006. Vol. 29 (6): 1110–9.
  8. Bonner-Weir S., Trent D.F., Honey R.N., Weir G.C. Responses of neonatal rat islets to streptozotocin: limited B-cell regeneration and hyperglycemia. Diabetes. 1981. Vol. 30 (1): 64–9.
  9. Gurley S.B., Clare S.E., Snow K.P., Hu A., Meyer T.W., Coffman T.M. Impact of genetic background on nephropathy in diabetic mice. American journal of physiology. 2006. Vol. 290 (1): F214–F222. DOI:10.1152/ajprenal.00204.2005.
  10. Dekel Y., Glucksam Y., Elron-Gross I., Margalit R. Insights into modeling streptozotocin-induced diabetes in ICR mice. Lab animal. 2009. Vol. 38 (2): 55–60. DOI:10.1038/laban0209-55.
  11. Axler D.A. Stability of the diabetogenic activity of streptozotocin. IRCS Medical Science. 1982. Vol. 10: 157–8.
  12. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia. 2008. Vol. 51 (2): 216–26. DOI: 10.1007/s00125-007-0886-7.
  13. Ninova D., Dean P.G., Deeds M., Stegall M.D. A novel model of allograft rejection: immune reconstitution of Rag-1 recipients with 2C transgenic T-cell receptor lymphocytes // Transplant International. 2005. Vol. 18 (1): 101–10. DOI:10.1111/j.1432-2277.2004.00012.x.
  14. Junod A., Lambert A.E., Orci L., Pictet R., Gonet A.E., Renold A.E. Studies of the diabetogenic action of streptozotocin. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine. 1967. Vol. 126 (1): 201–5.
  15. West E. Simon O.R., Morrison E.Y. Streptozotocin alters pancreatic beta-cell responsiveness to glucose within six hours of injection into rats. West Indian Med J. – 1996. Vol. 45: 60–2.
  16. Julio E. Ayala Standard operating procedures for describing and performing metabolic tests of glucose homeostasis in mic. Disease Models & Mechanisms. – 2010: 1–10.

You may be interested